{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-009762","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.628850+00:00","generated_at":"2026-06-17T08:50:26.987315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rockwell Medical Q4 revenue $19.3M, up 26% YoY; net loss narrows to $2.4M; guides FY2023 sales $78-82M","bullets":["Q4 2022 revenue $19.3M (+26% YoY); full-year revenue $72.8M (+17.6% YoY), highest ever.","Net loss Q4 $2.4M ($0.20/share) vs $8.9M ($1.05) in Q4 2021; full-year net loss $18.7M ($1.89) vs $32.7M ($3.83).","Debt reduced to $10.0M at year-end from $21.6M at end of 2021; cash used in ops improved to $17.4M from $33.5M.","2023 guidance: net sales $78-82M, gross profit $7-9M; focus on hemodialysis concentrates growth and profitability.","Reacquired distribution rights from Baxter for >700 hemodialysis customers; new CEO Mark Strobeck joined July 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-009762","json":"https://secwatch.observer/filing/0001628280-23-009762.json","markdown":"https://secwatch.observer/filing/0001628280-23-009762.md","text":"https://secwatch.observer/filing/0001628280-23-009762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/rmti-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:50:26.987315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27c178177db128acdb1af8a2165a89a5b1adc0b2","claim":"ROCKWELL MEDICAL, INC. reported 2023 results: revenue $78.0 Million to $82.0 Million. Guidance initiated.","evidence_excerpt":"Rockwell projects its 2023 guidance as follows: Net Sales $78.0 Million to $82.0 Million Gross Profit $7.0 Million to $9.0 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"$78.0 Million to $82.0 Million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b4f002e07ebafce802ae726b37e7f785142cc1f9","claim":"ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2022 results: revenue $72.8 million, net income $18.7 million, EPS $1.89 per share.","evidence_excerpt":"of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6% increase year-over-year and the highest full-year revenue to date for the Company • Reduced debt to $10.0 million at December 31, 2022, representing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2022"},{"label":"Revenue","value":"$72.8 million"},{"label":"Net income","value":"$18.7 million"},{"label":"EPS","value":"$1.89 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bd7aad549ca8def3d267eb53eaf22add7f1be164","claim":"ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2022 results: revenue $19.3 million, net income $2.4 million, EPS $0.20 per share.","evidence_excerpt":"--- Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results • Achieved third consecutive quarter of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$19.3 million"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}